Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial
Sanjoy Chatterjee(Tata Medical Center), Sandip Ganguly(Regeneron (United States)), S. Mandal(Bose Institute), Abha Kumari, Shagun Misra, Debdeep Dey(University of Ghana), Selvamani Backianathan(University of Tsukuba), Henry Finlay Godson, Santam Chakraborty(Tata Medical Center), Subhash C. Gupta, Debashree Guha, K.J. Maria Das, Rajesh Balakrishan, Anurupa Mahata(Tata Medical Center), Rosina Ahmed(Tata Medical Center), Punita Lal, Patricia Solomon
Cited by 29
Related Papers
Human papillomavirus in head and neck cancer in India: Current status and consensus recommendations
|South Asian Journal of Cancer|2017|48
HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results – Interim analysis
|Radiotherapy and Oncology|2022|42
Resource requirements and reduction in cardiac mortality from deep inspiration breath hold (DIBH) radiation therapy for left sided breast cancer patients: A prospective service development analysis
|Practical Radiation Oncology|2018|32
Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity
|European Journal of Cancer|2022|29
Alleviating Morbidity From Locally Advanced Breast Cancer Using a Practical and Short Radiation Therapy Regimen: Results of the HYPORT Palliative Studies
|International Journal of Radiation Oncology*Biology*Physics|2023|22